All In Biotech

Drug Trial Radar · NCT01793090

EPI-743 in Cobalamin C Defect: Effects on Visual and Neurological Impairment

Phase 2, Double-Blind, Placebo Controlled Clinical Trial of EPI-743 in Subjects With Cobalamin C Defect

Last checked: Nov 20, 2026Latest source record: Apr 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jan 2013

Primary completion

Jul 2013

Study completion Feb 2017

Sponsor

Lead sponsor
Bambino Gesù Hospital and Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Catholic University of the Sacred Heart
First posted
Feb 15, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 1 year, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the research is to investigate the safety and efficacy of EPI-743 treatment in patients with Cbl-C defect and related visual and neurological impairment. Primary Endpoints will be the improvement in visual function as assessed by visual acuity and eye-hand coordination and manual dexterity. Secondary Endpoints will be the improvement in neurologic function, evaluated by a battery of age-appropriated psychophysical tests, and/or in objective electrophysiological tests such as Visual Evoked potentials (VEP) and Electroretinogram (ERG) and/or the change in serum markers of redox state.

Conditions

  • Methylmalonic Aciduria and Homocystinuria,Cblc Type
  • Genetic Disease
  • Retinopathy

Interventions

  • Epi-743Drug

    EPI- 743 in capsule or formulation comprised of USP/NF Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.

  • Placebo supplementationOther

    Placebo will be administered in the same formulation as the active comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Visual FunctionTime frame: Baseline, six months, twelve months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bambino Gesù Hospital and Research Institute

    Rome, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.